Financial Performance - The company's operating revenue for Q3 2021 was ¥744,304,252.04, a decrease of 0.94% compared to the same period last year[4] - The net profit attributable to shareholders was -¥9,963,674.44, representing a significant decline of 697.40% year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥18,072,105.28, down 192.72% from the previous year[4] - The basic earnings per share for the period was -¥0.0053, a decrease of 657.14% compared to the same period last year[4] - Net profit for the current period was -¥57,174,950.52, compared to -¥40,997,680.27 in the previous period, indicating a deeper loss[33] - The company reported a basic and diluted earnings per share of -¥0.0317, compared to -¥0.0263 in the previous period[36] Assets and Liabilities - The total assets at the end of the reporting period were ¥4,985,347,921.82, an increase of 3.41% compared to the end of the previous year[4] - The total liabilities of the company as of September 30, 2021, were approximately CNY 4.29 billion, an increase from CNY 4.09 billion at the end of 2020, representing a rise of about 4.9%[25] - The total liabilities increased to ¥4,884,685,581.14 from ¥4,662,960,688.48, marking a growth of 4.7%[29] - The total equity attributable to shareholders decreased to ¥74,772,530.44, a decline of 44.14% from the previous year-end[4] - The total equity attributable to shareholders of the parent company decreased to ¥74,772,530.44 from ¥133,846,160.94, a decline of 44.0%[29] Cash Flow - The company reported a net cash flow from operating activities of ¥209,549,867.80, which increased by 57.13% year-to-date[4] - Cash flow from operating activities generated ¥2,156,184,193.26, compared to ¥1,993,388,963.26 in the previous period, showing an increase of 8.2%[38] - Operating cash inflow totaled CNY 2,184,543,218.48, an increase of 8.1% from CNY 2,021,131,578.67 in the previous period[41] - Net cash flow from operating activities was CNY 209,549,867.80, compared to CNY 133,361,873.25, representing a 57.1% increase[41] - Cash inflow from financing activities totaled CNY 352,074,000.00, down from CNY 563,590,000.00, a decrease of 37.4%[44] - Net cash flow from financing activities was -CNY 43,062,707.58, an improvement from -CNY 92,354,132.77[44] Expenses - The company's revenue increased, leading to a rise in tax expenses by 36.48% to ¥11,537,065.63[10] - Sales expenses rose by 35.36% to ¥208,258,609.05 due to increased promotional efforts in the pharmaceutical sector[10] - R&D expenditure significantly decreased by 97.64% to ¥38,487.99, indicating reduced investment in research and development[10] - Financial expenses decreased by 40.93% to ¥69,648,211.06, attributed to lower interest expenses from reduced borrowings[10] - Other income surged by 488.38% to ¥12,223,305.67, primarily due to increased government subsidies recognized during the reporting period[10] - The company reported a 40.72% increase in taxes paid, totaling ¥86,387,792.49, reflecting higher revenue[10] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 27,071, with no preferred shareholders[11] - The largest shareholder, Que Wenbin, holds 28.93% of the shares, amounting to 539,639,999 shares, which are currently frozen[14] Restructuring and Risks - The company continues to operate during the restructuring process, as approved by the court, allowing ongoing business activities[18] - The company is under a "delisting risk warning" due to the ongoing restructuring process, with its stock still trading under the name "*ST 恒康"[18] - There is a risk of bankruptcy if the restructuring plan is not approved by the court, which could lead to the termination of the company's stock listing[18] - The company has appointed management from Beijing Junhe Law Firm and Gansu Jiezhao Law Firm to oversee the restructuring process[18] Other Financial Metrics - The company experienced a 45.84% increase in prepaid accounts due to unsettled purchases during the reporting period[7] - Cash outflow for the acquisition of fixed assets rose by 45.61% to ¥137,330,673.49, indicating increased capital expenditures[10] - Cash received from loans decreased by 46.73% to ¥220,000,000.00, reflecting a reduction in bank borrowings compared to the previous year[10] - The company's current assets totaled approximately CNY 1.32 billion, up from CNY 1.20 billion at the end of 2020, indicating an increase of around 10.2%[22] - The company's cash and cash equivalents reached approximately CNY 212.92 million, compared to CNY 171.65 million at the end of 2020, reflecting a growth of about 24.1%[22] - The accounts receivable increased to approximately CNY 634.03 million from CNY 568.75 million, marking an increase of about 11.5%[22]

Financial Performance - The company's operating revenue for the first half of 2021 was CNY 1,479,996,718.59, representing a 17.79% increase compared to CNY 1,256,467,897.88 in the same period last year[26]. - The net profit attributable to shareholders of the listed company was a loss of CNY 49,109,956.06, which is a 2.79% increase in loss compared to a loss of CNY 47,776,912.52 in the previous year[26]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of CNY 27,855,153.20, showing a 47.21% improvement compared to a loss of CNY 52,765,252.67 in the same period last year[26]. - The net cash flow from operating activities was CNY 124,592,501.89, a decrease of 4.83% from CNY 130,916,111.00 in the previous year[26]. - The total assets at the end of the reporting period were CNY 4,894,329,740.83, reflecting a 1.53% increase from CNY 4,820,797,979.68 at the end of the previous year[26]. - The net assets attributable to shareholders of the listed company decreased by 36.69% to CNY 84,736,204.88 from CNY 133,846,160.94 at the end of the previous year[26]. - The basic and diluted earnings per share were both CNY -0.0263, a decrease of 2.73% compared to CNY -0.0256 in the same period last year[26]. - The weighted average return on net assets was -44.93%, a decline of 16.98% from -27.95% in the previous year[26]. Operational Developments - The company is currently undergoing a restructuring process, which carries the risk of potential bankruptcy if the restructuring fails[7]. - The company has established a professional hospital management team to enhance operational efficiency and service quality across its hospitals[41]. - The company has a strong market presence with a stable and professional sales team, focusing on academic promotion to enhance product brand influence[41]. - The company is committed to the dual-driven strategy of medical services and pharmaceutical manufacturing, with a focus on building regional medical centers[36]. - The company has been in the pharmaceutical industry for over 20 years, with its "Duyiwei" brand recognized as a famous trademark in China[36]. - The company has developed 36 types of pharmaceuticals, including 7 exclusive products nationwide and 12 products listed in the Chinese Pharmacopoeia (2020 edition)[36]. Financial Position and Liabilities - The company's debt-to-asset ratio stands at 97.72%, indicating a high level of debt risk[71]. - The company faces litigation with a total amount of approximately 1.3 billion yuan due to various disputes, contributing to its high debt levels[71]. - The company has entered a restructuring process, which carries the risk of potential bankruptcy if the restructuring fails[71]. - The company has not distributed cash dividends or bonus shares for the half-year period[78]. - The company has no stock incentive plans or employee stock ownership plans in place during the reporting period[79]. - The company is actively monitoring healthcare reform policies to mitigate potential operational impacts from policy changes[71]. Revenue Breakdown - Medical service revenue reached ¥1,255,075,775.96, representing 84.80% of total revenue, with a year-on-year increase of 15.01%[45]. - The total revenue from the pharmaceutical segment was ¥218,328,400.17, accounting for 14.75% of total revenue, with a year-on-year growth of 36.93%[45]. Investments and Subsidiaries - The company has invested ¥59,200,000 in the JF Huayue (Taizhou) Asset Management Center, holding a 10% share as a limited partner[62]. - The company also committed ¥63,800,000 to the JF Huacai (Taizhou) Asset Management Center, maintaining a 10% stake as a limited partner[65]. - The company reported a net profit of ¥30,967,515.16 from its subsidiary Kangxian Duyiwei Biopharmaceutical Co., Ltd., contributing over 10% to the overall net profit[59]. - The total assets of Kangxian Duyiwei Biopharmaceutical Co., Ltd. amounted to ¥790,555,231.87, with a revenue of ¥167,245,079.46[59]. - The total assets of the subsidiary Siyang People's Hospital Co., Ltd. were reported at ¥564,336,129.41, generating revenue of ¥308,918,338.27[59]. Shareholder Information - As of June 30, 2021, the controlling shareholder, Mr. Que Wenbin, had 638,509,999 shares frozen, accounting for 34.23% of the total share capital[113]. - The largest shareholder, Que Wenbin, holds 34.23% of the shares, totaling 638,509,999 shares, with a decrease of 154,000,000 shares during the reporting period[157]. - The second-largest shareholder, Sichuan Industrial Revitalization Development Investment Fund Co., Ltd., holds 6.03% of the shares, totaling 112,500,000 shares[157]. - The total number of shares pledged, marked, or frozen is 636,557,230 shares, primarily by Que Wenbin[157]. Legal and Compliance Issues - The company is involved in a significant lawsuit regarding a performance commitment dispute, with the plaintiff claiming a compensation of 91.03 million CNY for unmet performance targets in 2017[101]. - The company has been ordered to pay 22.96 million CNY in a ruling related to a share transfer dispute, which includes 12 million CNY in attorney fees and penalties[101]. - A court ruling has mandated the company to pay 92.77 million CNY related to a share transfer payment dispute[101]. - The company is currently appealing a court decision requiring it to pay approximately 387.92 million CNY in partnership equity acquisition payments and overdue interest[104]. - The company faces a claim of 43.66 million CNY in another partnership equity acquisition dispute, which is also under appeal[104]. - The company is involved in a loan contract dispute where it is required to repay 60 million CNY in principal and interest[107]. - The company has been ordered to pay 48 million CNY in a loan contract dispute, where it is held liable as a guarantor[107]. - The company is facing an arbitration claim for approximately 2.5 million EUR in intermediary service fees[111]. Environmental and Social Responsibility - The company has not faced any environmental penalties during the reporting period and adheres to relevant environmental laws[83]. - The company is committed to environmental protection, with all environmental facilities operating normally and meeting regulatory standards[85].

Financial Performance - The company's revenue for Q1 2021 was ¥698,315,770.31, representing a 26.99% increase compared to ¥549,890,785.25 in the same period last year[9] - The net profit attributable to shareholders was -¥47,235,805.90, a decrease of 52.33% from -¥31,008,831.97 year-over-year[9] - The basic earnings per share were -¥0.0253, reflecting a 52.41% decline compared to -¥0.0166 in the same period last year[9] - The total net profit for the current period is -48,758,930.91, compared to -33,788,875.09 in the previous period, indicating a decline of approximately 44.4%[73] - The net loss attributable to shareholders of the parent company is -47,235,805.90, compared to -31,008,831.97 in the previous period, indicating a decline of approximately 52.1%[73] Cash Flow - The net cash flow from operating activities was ¥18,991,307.39, down 58.46% from ¥45,716,745.19 in the previous year[9] - Cash flow from operating activities for the current period is 674,090,769.74, an increase from 557,215,582.66 in the previous period, representing a growth of approximately 20.9%[84] - Cash outflow from operating activities was ¥667,010,716.80, compared to ¥522,033,690.44 previously, indicating a rise of about 27.8%[88] - Cash inflow from financing activities was ¥162,530,000.00, down from ¥230,030,000.00, representing a decrease of about 29.3%[90] - Net cash flow from financing activities improved to ¥3,803,312.23 from a negative ¥44,538,112.11, marking a significant turnaround[90] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,825,242,006.02, a slight increase of 0.09% from ¥4,820,797,979.68 at the end of the previous year[9] - The total liabilities of the company were CNY 4,716,163,645.73, up from CNY 4,662,960,688.48, marking an increase of about 1.1%[56] - The company's total equity decreased to CNY 1,360,811,257.71 from CNY 1,402,424,758.98, reflecting a decline in shareholder value[67] - The company's current assets totaled CNY 1,215,684,984.60, compared to CNY 1,198,964,378.98 at the end of 2020, reflecting a growth of approximately 1.5%[51] - Total current liabilities were CNY 4,088,291,472.05, including short-term borrowings of CNY 1,324,786,079.61[99] Shareholder Information - The total number of common shareholders at the end of the reporting period was 36,881[12] - The largest shareholder, Que Wenbin, held 34.23% of the shares, totaling 638,509,999 shares[12] - The company did not engage in any repurchase transactions among the top 10 shareholders during the reporting period[18] - The company did not engage in any share repurchase activities during the reporting period[39] Expenses - Total operating costs amounted to CNY 722,161,120.86, up from CNY 585,699,870.66, reflecting a significant increase in operational expenses[70] - Sales expenses surged by 34,962,782.57, marking a 178.86% increase as sales efforts intensified post-pandemic[23] - Financial expenses for the current period amount to 12,895,990.64, compared to 6,362,584.88 in the previous period, reflecting an increase of approximately 102.5%[77] - Research and development expenses were recorded at 0.00, a decrease of 524,273.55, indicating no investment in R&D during the reporting period[23] Other Income and Expenses - The company reported a non-operating income and expenses net loss of -¥17,444,461.52 for the period[9] - Other income rose significantly by 1,071,273.13, a 1789.84% increase, driven by higher government subsidies received during the reporting period[23] - The company reported other income of 5,067,377.23 for the current period, down from 8,582,452.23 in the previous period, a decrease of about 41.5%[73] Operational Challenges - The company faces significant uncertainty regarding its restructuring application, which may impact its operational stability and financial health[28] - The company has no significant contracts or commitments that were not fulfilled during the reporting period[44] - There were no securities or derivative investments reported during the period[40][41] Audit Status - The first quarter report was not audited[107]

Business Model and Strategy - The company reported a significant shift from a single pharmaceutical manufacturing business to a dual-driven model focusing on medical services and pharmaceutical manufacturing, aligning with the "big health" industry strategy[21] - The company’s main business operations have expanded to include a variety of healthcare services, reflecting a strategic pivot in its business model[21] - The company aims to strengthen partnerships with top health service institutions and explore new high-end medical services[38] - The company is committed to deepening the development of unique Tibetan medicine products, aligning with national strategies for traditional medicine protection and innovation[39] - The company plans to implement the "hospital+" model to optimize resource allocation and address supply-demand issues in healthcare[108] - The company aims to increase drug sales revenue and brand influence through enhanced technology research and development and brand promotion efforts[132] - The company is exploring potential mergers and acquisitions to enhance its service offerings and market share[174] Financial Performance - The company plans not to distribute cash dividends, issue bonus shares, or increase share capital from reserves for the fiscal year[6] - The company has received an unqualified audit report from Asia Pacific (Group) CPA, ensuring the accuracy and completeness of the financial statements[5] - The company has not disclosed specific future performance forecasts, emphasizing the uncertainty of achieving strategic goals due to market conditions[5] - The company’s financial report indicates a commitment to transparency and risk disclosure, with detailed descriptions of potential risks included in the report[5] - The company reported a basic and diluted earnings per share of -¥0.028, an improvement of 97.89% from -¥1.350 in 2019[23] - The company reported a net loss of 52.24 million CNY for 2020, with no cash dividends proposed for the year[116] - The company has not distributed cash dividends for the past three years due to continuous losses, with net losses of 2.52 billion CNY in 2019 and 1.42 billion CNY in 2018[119] - The company’s asset-liability ratio stands at 96.73%, indicating a high level of debt risk[112] Revenue and Expenses - The company's operating revenue for 2020 was ¥2,805,895,494.80, a decrease of 23.85% compared to ¥3,684,467,721.58 in 2019[23] - The company achieved total revenue of CNY 2.81 billion in 2020, a year-on-year decrease of 23.85%, with the medical services segment contributing CNY 2.37 billion, accounting for 84.62% of total revenue[56] - Service revenue accounted for 85.02% of total revenue, while industrial revenue made up 14.98%[64] - Medical service revenue was ¥2,374,437,844.47, down 2.32% from the previous year[64] - Gross profit margin for industrial revenue was 77.77%, while for service revenue it was 19.44%[68] - Sales expenses decreased by 8.95% to ¥223,099,998.35 due to pandemic-related restrictions[79] - Management expenses dropped by 43.31% to ¥337,739,590.33, primarily due to a reduced consolidation scope[79] - Financial expenses decreased by 64.53% to ¥139,922,838.34, attributed to lower interest expenses and exchange losses[79] Operational Metrics - The company operates 11 hospitals, including 1 tertiary hospital and 8 secondary or higher-level hospitals, focusing on regional medical centers[38] - The company expanded its academic promotion activities, conducting nearly 300 events in the second half of 2020 to enhance product recognition among doctors and patients[59] - The company added over 1,500 grassroots hospitals and more than 500 grade hospitals in 2020, effectively compensating for the decline in hospital medication usage due to the pandemic[59] - The hospital bed occupancy rate in China was 80.7% in 2019, indicating a high demand for inpatient services[45] - The number of patients served increased by 20% compared to the previous year, reaching 1.2 million patients[174] Market and Industry Trends - The healthcare industry in China is experiencing rapid growth, driven by an aging population and increasing healthcare awareness, with a significant rise in demand for medical services[40] - In 2019, the total healthcare expenditure in China reached CNY 65,195.9 billion, a year-on-year increase of 12.41%, with per capita healthcare expenditure at CNY 4,656.7[45] - The number of medical institutions in China increased to 1,007,545 by the end of 2019, with private hospitals growing by 6.90% year-on-year to 22,424[44] - The company is positioned to benefit from ongoing healthcare reforms aimed at addressing the challenges of accessibility and affordability in medical services[50] - The government has outlined a 10-year plan for healthcare reform, focusing on building a balanced and comprehensive medical insurance system by 2030[43] Risks and Challenges - The company is facing risks related to policy changes in the healthcare sector, which could impact its operations[112] - The company acknowledges the scarcity of high-quality medical talent as a significant risk factor affecting its service development[112] - The company is at risk of bankruptcy if its restructuring application is unsuccessful, which could lead to delisting[112] - The company faces a loan repayment obligation of ¥60 million to Huashang Bank, with ongoing litigation that may affect its financial position[154] - The company is involved in multiple lawsuits, including a claim for 91.03 million yuan related to performance compensation for 2017, which remains uncertain in its impact on future profits[145] Corporate Governance and Compliance - The company has established a comprehensive governance structure, with all board members present for the report's review, ensuring accountability[5] - The company has committed to ensuring the authenticity, accuracy, and completeness of restructuring application materials since January 20, 2016, and has strictly fulfilled this commitment[120] - The company has committed to strict compliance with relevant laws and regulations regarding share changes and has pledged to avoid any illegal trading activities[126] - The company has no reported penalties or rectifications during the reporting period, indicating compliance with regulations[155] Social Responsibility and Community Engagement - The company actively participated in COVID-19 pandemic response, deploying over 500 medical personnel to various prevention stations and screening over 300,000 individuals[192] - Total investment in poverty alleviation efforts amounted to approximately CNY 5.76 million, including CNY 5.23 million in funds and CNY 0.54 million in material donations[197] - The company helped 84 registered impoverished individuals to escape poverty during the reporting period[198] - The company provided free medical consultations and health education to rural communities through expert medical teams[197] - The company has maintained a commitment to environmental protection and improving product quality as part of its social responsibility efforts[192]

恒康医疗集团股份有限公司 2020 年第三季度报告全文 恒康医疗集团股份有限公司 2020 年第三季度报告 2020 年 10 月 1 恒康医疗集团股份有限公司 2020 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人吕东明、主管会计工作负责人吕东明及会计机构负责人(会计主 管人员)王宁声明：保证季度报告中财务报表的真实、准确、完整。 2 恒康医疗集团股份有限公司 2020 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |-----------------------------------------------------|------------------|-------------------------|------------------|--------------- ...

Financial Performance - The company's operating revenue for the first half of 2020 was ¥1,256,467,897.88, a decrease of 32.19% compared to the same period last year[23]. - The net profit attributable to shareholders was a loss of ¥47,776,912.52, an improvement of 22.09% from a loss of ¥61,327,122.61 in the previous year[23]. - The net cash flow from operating activities was ¥130,916,111.00, down 24.19% from ¥172,683,256.46 in the same period last year[23]. - The total assets at the end of the reporting period were ¥4,827,576,486.12, a decrease of 1.68% from the previous year-end[23]. - The net assets attributable to shareholders decreased by 24.53% to ¥147,022,627.03 compared to ¥194,799,539.55 at the end of the previous year[23]. - The basic earnings per share were -¥0.0256, an improvement of 22.19% from -¥0.0329 in the same period last year[23]. - The weighted average return on net assets was -27.95%, a decline of 25.66% compared to -2.29% in the previous year[23]. - The company achieved total revenue of ¥1,256.47 million, a year-on-year decrease of 32.19%, with the medical segment generating ¥1,091.27 million (down 33.31%) and the pharmaceutical segment generating ¥159.44 million (down 16.13%)[56]. - The net profit attributable to shareholders was -¥47.77 million, an increase of 22.09% year-on-year, indicating a reduction in losses compared to the previous period[56]. - The operating cost decreased by 29.53% to ¥954,460,331.51 from ¥1,354,495,794.64 year-on-year[63]. - The company reported a significant reduction in income tax expenses, which fell by 65.80% to ¥17,188,302.10 from ¥50,251,202.59 year-on-year[63]. Operational Highlights - The company operates 12 hospitals, including 1 tertiary hospital and 9 secondary or higher-level hospitals, with nearly 8,000 open beds and approximately 300,000 outpatient visits annually[36]. - During the reporting period, outpatient services reached approximately 1.1 million visits, while inpatient services totaled around 100,000 visits, with the medical services segment accounting for 86.85% of total revenue[58]. - The pharmaceutical segment maintained stable sales performance, generating ¥159.44 million, which accounted for 12.69% of total revenue, despite challenges posed by the pandemic[62]. - The company has established a professional hospital management team and implemented a standardized management model to enhance operational efficiency and quality control[49]. - The company emphasizes improving medical quality and safety, especially during the pandemic, to ensure patient safety[42]. Strategic Initiatives - The company aims to enhance its marketing network and adjust sales strategies to improve market coverage for its pharmaceutical products[43]. - The company is focused on developing high-end domestic medical services and exploring collaborations with top health institutions and research organizations[38]. - The company has highlighted potential risks in its future development strategy and performance planning[6]. - The company has not disclosed any significant new product or technology developments in this report[6]. - The company has increased its construction projects by 2.82% compared to the beginning of the period, mainly due to ongoing renovation projects[44]. Risks and Challenges - The company is facing risks related to policy changes in the healthcare sector, which may impact operations[91]. - The company acknowledges the risk of medical service delivery due to various factors, including individual patient differences and potential medical disputes[91]. - The company recognizes the challenge of attracting and retaining high-quality medical and management talent in the competitive healthcare industry[91]. - The company is facing litigation with a total amount of approximately 1.1 billion yuan, which contributes to its high debt levels[92]. - If the company's audited net profit for 2020 remains negative, it may face delisting risks according to the Shenzhen Stock Exchange regulations[92]. - The company has received a restructuring application from creditors due to significant debt and potential insolvency, which introduces uncertainty regarding its financial future[104]. Shareholder and Governance Information - As of June 30, 2020, the controlling shareholder's shares totaling 792,509,999, representing 42.49% of the total share capital, have been frozen due to debt disputes[122]. - The controlling shareholder has delegated voting rights for 12.59% and 29.90% of the company's shares to two investment management companies[123]. - The company did not experience any changes in its controlling shareholder or actual controller during the reporting period, ensuring stability in governance[181]. - The total number of shareholders holding more than 5% of the shares includes 10 major shareholders, with no changes reported during the period[176]. - The company has appointed new directors and executives, including a new president, to support its development needs[193]. Community and Social Responsibility - The company invested approximately 2.82 million in targeted poverty alleviation efforts, including 2.29 million in cash and 0.52 million in material donations[154]. - The company helped 4 registered impoverished individuals to escape poverty during the reporting period[159]. - The investment in poverty alleviation projects for industrial development was 0.81 million, while assistance for impoverished disabled individuals amounted to 1.41 million[159]. - The company plans to continue its poverty alleviation efforts in the second half of 2020, focusing on industrial and health-related initiatives[160].

恒康医疗集团股份有限公司 2020 年第一季度报告全文 恒康医疗集团股份有限公司 2020 年第一季度报告 2020 年 04 月 1 恒康医疗集团股份有限公司 2020 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人王伟、主管会计工作负责人王伟及会计机构负责人(会计主管人 员)王宁声明：保证季度报告中财务报表的真实、准确、完整。 2 恒康医疗集团股份有限公司 2020 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | |-----------------------------------------------------|------------------|------------------|---------------------------| | □ 是 √ 否 | 本报告期 | 上 ...

Business Model and Strategy - The company reported a shift from a single pharmaceutical manufacturing business to a dual-driven model focusing on medical services and pharmaceutical manufacturing, emphasizing a "big health" industry strategy[22] - The company plans to enhance collaboration with internationally certified molecular diagnostic laboratories to support health management and biomedical research[39] - The company aims to pursue a leading position in the Chinese traditional Chinese medicine industry with a strategy of "seeking development in stability and stability in development"[40] - The company plans to adjust its sales strategy by optimizing product structure and pricing systems, targeting specific regional markets[40] - The company is committed to enhancing its academic support and clinical research services to better serve doctors and patients nationwide[40] - The company plans to enhance internal management and expand the pharmaceutical market in 2020, focusing on a dual-driven strategy[108] - The company aims to strengthen group management and integration of hospitals, with a focus on developing core and specialty disciplines[108] - The company plans to focus resources on core businesses such as medical services and pharmaceutical manufacturing in 2020, aiming to enhance its competitive edge in regional healthcare services[139] - The company will optimize its sales strategy and product structure, targeting key products to boost market coverage and sales growth[111] Financial Performance - The company's operating revenue for 2019 was ¥3,684,467,721.58, a decrease of 4.01% compared to ¥3,838,392,197.48 in 2018[24] - The net profit attributable to shareholders for 2019 was -¥2,519,543,757.96, representing a decline of 77.71% from -¥1,417,817,723.30 in 2018[24] - The total assets at the end of 2019 were ¥4,909,889,865.73, a decrease of 43.94% from ¥8,758,983,757.39 at the end of 2018[24] - The net assets attributable to shareholders decreased by 92.81% to ¥194,799,539.55 at the end of 2019, down from ¥2,711,131,540.28 at the end of 2018[24] - The company reported a total profit of CNY -2.44 billion, a decline of 82.70%, and a net profit attributable to shareholders of CNY -2.52 billion, down 77.71%[58] - The company reported a net loss of approximately ¥2.52 billion in 2019, following a loss of about ¥1.42 billion in 2018, indicating ongoing financial challenges[120] Revenue Breakdown - In 2019, the company achieved total revenue of CNY 3.68 billion, a year-on-year decrease of 4.01%, with the medical segment generating CNY 3.20 billion, up 3.76%, and the pharmaceutical segment generating CNY 429 million, up 12.89%[58] - The medical services segment accounted for 86.94% of total revenue[60] - The pharmaceutical segment's sales revenue reached CNY 429 million, representing 11.65% of total revenue, with a year-on-year growth of 12.89%[61] - Service revenue represented 86.94% of total revenue, with a slight decline of 2.56% to approximately ¥3.20 billion[66] - Pharmaceutical revenue increased by 9.34% to approximately ¥419 million, representing 11.37% of total revenue[66] Operational Changes and Management - The company optimized resource allocation and strengthened internal management, significantly enhancing its risk resistance capabilities[40] - The company reduced management expenses to CNY 588 million in 2019, a decrease of CNY 49 million year-on-year[64] - The company established three committees for academic and management purposes to enhance the quality of medical services and internal management[59] - The company is focused on enhancing its core competitiveness and risk resistance capabilities[141] - The company is currently involved in arbitration regarding a claim for approximately 2.5 million euros in intermediary service fees[167] Audit and Compliance - The company has engaged Asia Pacific (Group) CPA Firm to provide an unqualified audit report for the financial statements[6] - The independent directors confirmed the audit report for the 2019 financial year as accurate and reflective of the company's financial status[141] - There were no significant accounting errors requiring restatement during the reporting period[146] - The company has not faced any bankruptcy reorganization issues during the reporting period[157] Shareholder and Governance Issues - The company has not distributed cash dividends for 2019 and 2018 due to losses, and no plans for stock dividends or capital reserve transfers were made[116] - The company has a clear development path for its hospitals, focusing on comprehensive hospital development as a primary strategy[108] - The actual controller has committed to avoiding any direct or indirect competition with the company since September 2014, and has strictly fulfilled this commitment[124] - The company has confirmed that all directors are responsible for the authenticity and completeness of the non-public offering application documents as of June 5, 2015, and have strictly fulfilled this commitment[127] Market and Industry Context - In 2018, the total number of medical and health institutions in China reached 997,434, with private hospitals increasing by 11.82% to 20,977[46] - The total health expenditure in China for 2018 was approximately 57,998.3 billion yuan, a year-on-year increase of 10.27%[47] - In 2018, the total number of outpatient visits in medical institutions reached 8.31 billion, with private hospitals seeing an 8.16% increase in visits[50] Future Plans and Commitments - The company plans to enhance its talent management and corporate culture to build an efficient and capable workforce[140] - Increased investment in research and development is planned to strengthen the company's core competitiveness and sustainable growth[111] - The company will collaborate with renowned institutions to develop marketable and innovative pharmaceutical products[111] - The company has established a three-year shareholder return plan, prioritizing cash dividends when conditions allow[116]

Financial Performance - Net profit attributable to shareholders was a loss of approximately CNY 108.16 million, representing a 76.44% increase in loss compared to the same period last year[9]. - Operating revenue for the reporting period was approximately CNY 886.17 million, down 2.54% year-on-year[9]. - Basic earnings per share were -CNY 0.0580, a decrease of 76.43% compared to the same period last year[9]. - The weighted average return on net assets was -4.11%, a decrease of 6.89% compared to the same period last year[9]. - The company reported a net loss of CNY 485,150,120.75 in retained earnings, compared to a loss of CNY 305,767,384.61 in the previous period[46]. - The net profit for the current period was CNY 825,720,129.81, a significant recovery from a net loss of CNY 25,107,771.19 in the previous period[71]. - The total profit for the current period was CNY 825,720,129.81, compared to a total loss of CNY 25,107,771.19 in the previous period[71]. - The company reported a total comprehensive income for the current period of CNY 825,720,129.81, a recovery from a loss of CNY 25,107,771.19 in the previous period[71]. - The company's total comprehensive income amounted to -152,414,316.72, compared to -389,454,137.96 in the previous period, indicating an improvement[80]. Assets and Liabilities - Total assets at the end of the reporting period were approximately CNY 8.43 billion, a decrease of 3.74% compared to the end of the previous year[9]. - Total current assets as of September 30, 2019, were CNY 2,057,901,206.38, a decrease of 10.4% from CNY 2,296,954,293.94 as of December 31, 2018[40]. - Total liabilities as of September 30, 2019, were CNY 5,775,111,296.23, down from CNY 5,901,333,608.49, a decrease of 2.1%[43]. - The company's total assets were CNY 8,431,747,674.79, down from CNY 8,758,983,757.39, a decrease of 3.7%[40]. - The total liabilities decreased to ¥2,192,061,826.47 from ¥2,440,871,122.42, a reduction of approximately 10.2%[56]. - The company’s total liabilities included short-term borrowings of ¥1,288,000,000.00, unchanged from the previous period[108]. - Total liabilities amounted to CNY 5,901,333,608.49, with current liabilities at CNY 2,964,779,474.64[115]. - The company has a total of CNY 1,069,310,000.00 in other non-current liabilities, reflecting potential future obligations[115]. Cash Flow - The net cash flow from operating activities was approximately CNY 254.15 million, an increase of 263.18% compared to the same period last year[9]. - Cash and cash equivalents decreased by 52.00% to ¥166,689,474.68 due to repayment of bank loans[21]. - The company reported a cash inflow from operating activities of 2,830,643,898.39, compared to 2,770,255,280.80 in the previous period, reflecting a positive trend[90]. - Cash flow from operating activities generated a net amount of ¥195,758,705.04, compared to a net outflow of ¥253,535,249.23 in the previous period, indicating a significant improvement[101]. - The total cash inflow from operating activities was ¥346,954,797.55, significantly higher than ¥27,042,792.82 in the previous period[101]. - The ending balance of cash and cash equivalents was ¥45,164,478.44, compared to ¥7,944,943.84 at the end of the previous period, showing a substantial increase[104]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 49,485[13]. - The largest shareholder, Que Wenbin, held 42.49% of the shares, totaling approximately 792.51 million shares[13]. - The company did not conduct any repurchase transactions among the top ten shareholders during the reporting period[16]. Expenses and Investments - Research and development expenses surged by 1722.53% to ¥1,065,089.62, reflecting increased investment in the soft bag project[21]. - Financial expenses rose by 51.97% to ¥265,309,378.09, driven by decreased foreign exchange gains and increased interest expenses[21]. - The company incurred management expenses of CNY 10,646,005.26, up from CNY 7,044,452.93 in the last period[68]. - The company recorded a credit impairment loss of CNY 851,493,845.62, indicating a significant financial impact[68]. - The investment income for the current period was 14,207,183.42, compared to 8,618.00 in the previous period, indicating growth in investment performance[85]. Other Financial Metrics - The company reported non-operating income of approximately CNY 12.65 million for the period[9]. - Other income increased by 1286.14% to ¥2,079,204.54, primarily from increased government subsidies[21]. - The company experienced a 33.31% reduction in taxes paid, amounting to ¥112,927,219.49, due to a decline in revenue[21]. - The company reported a significant decrease in interest expenses, with current interest expenses at ¥85,365,483.17 compared to ¥74,893,293.13 in the previous period[57]. - The company received tax refunds amounting to 247,137.43, compared to 1,471.17 in the previous period, indicating improved tax management[90]. Market Strategy - The company is focusing on expanding its market presence and enhancing product development strategies[120].

Financial Performance - Total revenue for the first half of 2019 was CNY 1,853,036,019.05, a decrease of 0.48% compared to CNY 1,862,057,207.53 in the same period last year[22]. - Net profit attributable to shareholders was CNY -61,327,122.61, representing a decline of 184.80% from CNY 72,317,026.90 in the previous year[22]. - The net profit after deducting non-recurring gains and losses was CNY -75,502,570.70, a decrease of 214.54% compared to CNY 65,920,504.82 last year[22]. - The net cash flow from operating activities was CNY 172,683,256.46, down 11.17% from CNY 194,395,235.91 in the same period last year[22]. - Basic earnings per share were CNY -0.0329, a drop of 184.79% from CNY 0.0388 in the previous year[22]. - The total profit for the period was RMB 1,416,220, a significant decline of 91.36% compared to the previous year[46]. - The medical services segment generated total revenue of RMB 163,630,890, down 1.84% year-on-year, with outpatient revenue at RMB 33,182,580 and inpatient revenue at RMB 83,990,580[47]. - The pharmaceutical manufacturing segment reported sales revenue of RMB 21,051,550, an increase of 15.09% year-on-year, with a profit of RMB 2,780,100[48]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 8,595,259,655.22, a decrease of 1.87% from CNY 8,758,983,757.39 at the end of the previous year[22]. - Net assets attributable to shareholders were CNY 2,673,464,972.48, down 1.39% from CNY 2,711,131,540.28 at the end of the previous year[22]. - Cash and cash equivalents at the end of the reporting period amounted to ¥213,230,516.80, representing 2.48% of total assets, a decrease of 0.67% compared to the previous year[58]. - Accounts receivable increased to ¥1,554,284,321.17, accounting for 18.08% of total assets, up 1.79% from the previous year[60]. - Inventory decreased significantly to ¥275,764,622.66, representing 3.21% of total assets, down 5.68% year-on-year[60]. - Short-term borrowings decreased to ¥1,357,000,000.00, making up 15.79% of total liabilities, a reduction of 10.58% compared to the previous year[60]. - Long-term borrowings increased to ¥1,507,419,211.82, accounting for 17.54% of total liabilities, an increase of 14.54% year-on-year[60]. Strategic Initiatives - The company plans not to distribute cash dividends or issue bonus shares[7]. - The company plans to expand its sales team to enhance market coverage for its quality pharmaceutical products[39]. - The company aims to integrate clinical resources to support health management and biomedical research, enhancing its service offerings[35]. - The company plans to strengthen its core industries and optimize the management of marginal assets to ensure long-term stability[46]. - The company plans to continue its poverty alleviation efforts in the second half of 2019, focusing on industrial and health poverty alleviation[151]. Risks and Challenges - The company has acknowledged the presence of various risks that may affect future performance, as detailed in the report[6]. - The company faces policy risks due to potential adjustments in healthcare reform policies that may impact operations[82]. - The company is experiencing high debt risks due to the uncertainty surrounding its controlling shareholder's stock being frozen by the court[82]. - The company recognizes the risks associated with medical services due to individual patient differences and the quality of medical personnel[82]. - The company acknowledges the scarcity of high-quality medical and management talent as a key factor affecting its development in the medical services sector[82]. Shareholder and Governance Issues - The company has not made any commitments regarding capital reserve transfers to increase share capital during the reporting period[85]. - The company held several temporary shareholder meetings with participation rates ranging from 14.65% to 42.57%[85]. - The company confirmed that it will take measures to exit competitive businesses in a manner that maximizes the interests of Hengkang Medical, including stopping operations that may constitute competition[91]. - The company has confirmed that all commitments made by its controlling shareholders are independently enforceable, ensuring shareholder rights are protected[91]. - The company is subject to regulatory requirements regarding the management of shares held by executives and major shareholders[162]. Legal and Compliance Matters - There are no significant litigation or arbitration matters reported during the reporting period, ensuring no adverse legal impacts on the company[100]. - The company has not experienced any bankruptcy restructuring matters during the reporting period, indicating financial stability[99]. - The company has not faced any non-standard audit reports in the previous year, reflecting a clean audit history[99]. - The semi-annual financial report for 2019 was not audited, which may impact the reliability of the financial data presented[196]. Social Responsibility - The company actively participated in social responsibility initiatives, including health poverty alleviation and community support activities[146]. - The company invested approximately 510.96 million in poverty alleviation efforts, helping 635 registered impoverished individuals to escape poverty[146]. - The investment in health poverty alleviation was about 23 million, while the investment for helping impoverished disabled individuals was approximately 213.8 million, benefiting 1,984 individuals[146]. - The company received the "Outstanding Contribution Award for Poverty Alleviation" in Gansu for the year 2018[146].